You are here: Home / News / TRADE / Test rapigen: the super strong new crown mutant swept the United States

Test rapigen: the super strong new crown mutant swept the United States

Publish Time: 2022-06-10     Origin: Site

Test rapigen: the super strong new crown mutant swept the United States

Wave after wave!

Facing the continuous spread of monkeypox, more and more countries have "sounded the alarm". On June 8 local time, the data released on the official website of the United States Centers for Disease Control and prevention showed that monkeypox cases had occurred in 29 countries around the world, and the cumulative number of confirmed cases reached 1088. The CDC has raised the monkeypox Outbreak Alert to level 2; The British health and Safety Authority announced that monkeypox would be listed as a legal infectious disease in the UK from June 8; On June 8, the Korean government announced that monkeypox was designated as a class II legal infectious disease.

In order to cope with the potential risk of transmission, the United States said that 36000 doses of vaccine were being distributed to high-risk groups who had been exposed to the virus. In addition, both Britain and Germany said that they had placed an order to purchase monkeypox vaccine jynneos from Bavaria Nordic company. This makes monkeypox vaccine the focus.

At the same time, new changes have taken place in the situation of the COVID-19 in the United States. On June 8 local time, NBC reported that the fastest spreading new subtype of Omicron ba 4、BA. 5 strain has spread rapidly in the United States, and is likely to become the main epidemic strain in the United States.

It is worth noting that compared with Omicron ba 2 strain, ba 4、BA. The transmissibility of the 5 strain was further enhanced. The European Center for Disease Control and prevention reported that Portugal expected ba 5 relative ba 2 with a growth advantage of 13%, and South Africa expects ba 5. The growth advantage was 12%, and it was the mutant with the fastest transmission speed at present.

Sudden escalation of Outbreak Alert

On June 8 local time, the data released on the official website of the United States Centers for Disease Control (CDC) showed that monkeypox cases had occurred in 29 countries around the world, and the cumulative number of confirmed cases reached 1088. Among them, the UK reported the largest number of cases, including 302 confirmed and suspected cases.

According to the latest data from the Spanish Ministry of health, as of June 7 local time, 439 samples of suspected monkeypox cases had been received in the country, of which 225 were positive, 27 more than on June 6.

In the face of the continuing spread of the epidemic, the US Centers for Disease Control and prevention has raised the monkeypox epidemic alert to level 2 and advised the public to "strengthen preventive measures" to contain the epidemic. It is reported that the highest level of the CDC's epidemic alert is level 3. If it is raised to level 3, the CDC will issue a warning on unnecessary travel.

As for the sudden escalation of the epidemic alarm, CDC explained that the current infection risk faced by the public is still not high. The purpose of raising the alarm level is to encourage people to avoid close contact with patients, including patients with skin or genital lesions, and sick or dead animals.

In addition to the United States, other countries are also upgrading prevention and control measures. Among them, the British health and Safety Authority announced that monkeypox would be listed as a legal infectious disease in the UK from June 8. All doctors in Britain must notify the local government of the suspected monkeypox patients.

On June 8, the Korean government announced that monkeypox was designated as a secondary legal infectious disease, and it planned to introduce the third generation monkeypox vaccine. It is negotiating with the vaccine production company, but the procurement scale and schedule have not been determined. It is reported that when a secondary infectious disease occurs or prevails, it must be reported within 24 hours, and the infected person must be isolated;

The Canadian government issued a warning on June 7 that "health precautions need to be strengthened" and reminded people to be alert to the spread of monkeypox virus when traveling to 27 countries such as the United States, Britain and Australia.

On Wednesday (June 8) local time, who director general Tan Desai said that monkeypox virus may have spread for some time in some non monkeypox endemic countries and regions without being found. The risk of monkeypox in non endemic countries is real. Who is worried about the risk of the virus to vulnerable groups such as children and pregnant women.

Tan Desai further pointed out that in African countries, so far this year, there have been more than 1400 suspected and confirmed cases, and 66 patients have died. Who urges affected countries to find all cases and contacts to control the epidemic and block its transmission. Who will also issue guidance on clinical care, infection prevention and control, vaccination and community protection in the coming days.

According to the who, monkeypox is a disease caused by monkeypox virus infection. It is closely related to the smallpox virus that has been eradicated. It is a zoonotic virus. The incubation period of monkeypox can reach 5-21 days. Its infection symptoms generally include skin rash, fever, headache, muscle pain, swelling and low back pain. Most patients usually recover after 14-21 days of symptoms, but some patients have serious symptoms or even death.

COOPERATION INTENTION PLEASE LEAVE YOUR EMAIL

Leave your email address, we will send professional service personnel to establish communication with you.  

During the period, we will strictly comply with the terms of stealth service to ensure your information security.  

COOPERATION INTENTION PLEASE LEAVE YOUR EMAIL
  Henan UDX Biotechnology Co.,Ltd
   Building 2,No.206, Xisihuan Road,High-tech Industrial Development Zone, Zhengzhou, Henan China
   marina@udxbio.com
  +86-371-88915816
  +86-371-88915816
    +86-153-33817530
© Copyright  2021 Henan UDX Biotechnology Co.,Ltd. All rights reserved. | Sitemap